Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bausch Health Companies Inc (BHC)

Bausch Health Companies Inc (BHC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,156,672
  • Shares Outstanding, K 351,884
  • Annual Sales, $ 8,380 M
  • Annual Income, $ -4,148,000 K
  • 60-Month Beta 0.78
  • Price/Sales 0.97
  • Price/Cash Flow 1.88
  • Price/Book 2.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 1.07
  • Number of Estimates 8
  • High Estimate 1.34
  • Low Estimate 0.94
  • Prior Year 0.93
  • Growth Rate Est. (year over year) +15.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.73 +1.98%
on 07/17/19
25.90 -10.50%
on 07/03/19
+0.30 (+1.31%)
since 06/19/19
3-Month
20.27 +14.36%
on 06/03/19
26.79 -13.48%
on 05/08/19
+0.05 (+0.22%)
since 04/18/19
52-Week
17.20 +34.77%
on 12/26/18
28.45 -18.52%
on 10/03/18
+0.51 (+2.25%)
since 07/19/18

Most Recent Stories

More News
Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall

Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.

NVS : 93.56 (-0.74%)
AXGT : 7.09 (-7.56%)
BHC : 23.18 (+0.35%)
ETON : 6.58 (-1.05%)
Is Bausch Health (BHC) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

BHC : 23.18 (+0.35%)
Aerie Completes Enrollment Under Rhopressa Study in Japan

Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.

AERI : 23.12 (-2.12%)
NVS : 93.56 (-0.74%)
BHC : 23.18 (+0.35%)
PFE : 42.77 (-0.67%)
Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.

DOVA : 16.02 (-0.19%)
ADMS : 6.00 (-0.50%)
BHC : 23.18 (+0.35%)
ACST : 1.71 (+8.23%)
Dova Receives Approval for Doptelet in Europe, Stock Up

Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

DOVA : 16.02 (-0.19%)
NVS : 93.56 (-0.74%)
RIGL : 2.41 (-3.21%)
BHC : 23.18 (+0.35%)
Is Bausch Health (BHC) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

BHC : 23.18 (+0.35%)
Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%

Bausch Health (BHC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

ADMS : 6.00 (-0.50%)
BHC : 23.18 (+0.35%)
Is Bausch Health (BHC) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

BHC : 23.18 (+0.35%)
Why Is Bausch (BHC) Down 16.2% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BHC : 23.18 (+0.35%)
Is Bausch Health (BHC) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

BHC : 23.18 (+0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade BHC with:

Business Summary

Bausch Health Companies Inc. develops and distributes drugs. It develops drugs for unmet medical needs in central nervous system disorders and distributes generic and branded generic drugs primarily in Latin America and Eastern Europe. Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 23.46
1st Resistance Point 23.32
Last Price 23.18
1st Support Level 22.97
2nd Support Level 22.76

See More

52-Week High 28.45
Fibonacci 61.8% 24.15
Last Price 23.18
Fibonacci 50% 22.83
Fibonacci 38.2% 21.50
52-Week Low 17.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar